Showing results (11-20 of 55) with videos related to

Sort By:
Pageof 6
Leukemia Research|December 21, 2010
Successful treatment with a modified bortezomib schedule of weekly and longer intervals for patients with refractory/resistance multiple myelomaMichihide Tokuhira, Reiko Watanabe, Tomoe Nemoto, et al.
The Journal of Rheumatology|September 6, 2005
Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositisHideto Kameda, Hayato Nagasawa, Hiroe Ogawa, et al.
Leukemia & Lymphoma|April 11, 2015
Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphomaMorihiro Higashi, Michihide Tokuhira, Satoshi Fujino, et al.
Scientific Reports|June 27, 2020
Decreased MYC-associated factor X (MAX) expression is a new potential biomarker for adverse prognosis in anaplastic large cell lymphomaTakahisa Yamashita, Morihiro Higashi, Shuji Momose, et al.
Leukemia & Lymphoma|October 9, 2010
Y-box binding protein-1 expression in diffuse large B-cell lymphoma: an impact on prognosis in the rituximab eraKyoko Hanzawa, Shuji Momose, Morihiro Higashi, et al.
Pathology International|June 25, 2021
Fluorescent nanoparticle-mediated semiquantitative MYC protein expression analysis in morphologically diffuse large B-cell lymphomaNatsuko Takayanagi, Shuji Momose, Jun Kikuchi, et al.
The Journal of Pathology. Clinical Research|March 15, 2022
CD24 is a surrogate for 'immune-cold' phenotype in aggressive large B-cell lymphomaMorihiro Higashi, Shuji Momose, Natsuko Takayanagi, et al.
Cancers|April 13, 2024
Copy Number Analysis of 9p24.1 in Classic Hodgkin Lymphoma Arising in Immune Deficiency/DysregulationKumiko Ohsawa, Shuji Momose, Asami Nishikori, et al.
Cancer Science|December 19, 2019
Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center-derived B-cell lymphomasYuka Tanaka, Shuji Momose, Takayuki Tabayashi, et al.
Cancer Science|January 24, 2015
TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activitiesMorihiko Sagawa, Takayuki Tabayashi, Yuta Kimura, et al.
Pageof 6